Compare Elder Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA STRIDES PHARMA SCIENCE ELDER PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -0.2 24.0 - View Chart
P/BV x 0.1 1.5 6.9% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ELDER PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
STRIDES PHARMA SCIENCE
Mar-18
ELDER PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3801,147 33.1%   
Low Rs188642 29.3%   
Sales per share (Unadj.) Rs491.2317.2 154.8%  
Earnings per share (Unadj.) Rs-3.27.8 -40.6%  
Cash flow per share (Unadj.) Rs14.425.1 57.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5274.3 137.3%  
Shares outstanding (eoy) m20.5489.50 22.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.8 20.5%   
Avg P/E ratio x-89.3114.0 -78.3%  
P/CF ratio (eoy) x19.735.7 55.2%  
Price / Book Value ratio x0.83.3 23.1%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m5,83380,058 7.3%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2,1794,341 50.2%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m10,08928,394 35.5%  
Other income Rs m257941 27.3%   
Total revenues Rs m10,34629,334 35.3%   
Gross profit Rs m-7923,965 -20.0%  
Depreciation Rs m3611,540 23.5%   
Interest Rs m2,7561,962 140.5%   
Profit before tax Rs m-3,6531,403 -260.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m3,713-436 -851.9%   
Tax Rs m12597 128.6%   
Profit after tax Rs m-65702 -9.3%  
Gross profit margin %-7.814.0 -56.2%  
Effective tax rate %-3.46.9 -49.4%   
Net profit margin %-0.62.5 -26.2%  
BALANCE SHEET DATA
Current assets Rs m9,24024,836 37.2%   
Current liabilities Rs m9,99818,993 52.6%   
Net working cap to sales %-7.520.6 -36.5%  
Current ratio x0.91.3 70.7%  
Inventory Days Days4671 65.3%  
Debtors Days Days60113 52.9%  
Net fixed assets Rs m10,12434,289 29.5%   
Share capital Rs m206895 23.0%   
"Free" reserves Rs m5,58223,651 23.6%   
Net worth Rs m7,73424,546 31.5%   
Long term debt Rs m4,88915,513 31.5%   
Total assets Rs m22,88265,437 35.0%  
Interest coverage x-0.31.7 -19.0%   
Debt to equity ratio x0.60.6 100.0%  
Sales to assets ratio x0.40.4 101.6%   
Return on assets %11.84.1 288.8%  
Return on equity %-0.82.9 -29.5%  
Return on capital %22.36.9 323.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,697 2.0%   
Fx outflow Rs m125735 17.0%   
Net fx Rs m18114,962 1.2%   
CASH FLOW
From Operations Rs m11,7541,871 628.3%  
From Investments Rs m-5615,826 -9.6%  
From Financial Activity Rs m-6,762-10,157 66.6%  
Net Cashflow Rs m4,432-2,615 -169.5%  

Share Holding

Indian Promoters % 39.6 27.7 143.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 16.8 8.6 195.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 25.9 139.4%  
Shareholders   16,479 56,241 29.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WYETH LTD  IPCA LABS  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

STRIDES PHARMA SCIENCE at 52 Week High; BSE 500 Index Up 0.5% (Market Updates)

Aug 11, 2020 | Updated on Aug 11, 2020

STRIDES PHARMA SCIENCE share price has hit a 52-week high. It is presently trading at Rs 628. BSE 500 Index is up by 0.5% at 14,843. Within the BSE 500, STRIDES PHARMA SCIENCE (up 2.1%) and NESCO (up 15.9%) are among the top gainers, while top losers are LAURUS LABS LTD and CAPLIN POINT.

LAURUS LABS LTD Share Price Down by 5%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Aug 11, 2020 | Updated on Aug 11, 2020

LAURUS LABS LTD share price is trading down by 5% and its current market price is Rs 1,160. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 4.4%) and SYNGENE INTERNATIONAL (up 1.9%). The top losers are LAURUS LABS LTD (down 5.2%) and STRIDES PHARMA SCIENCE (down 5.7%).

STRIDES PHARMA SCIENCE Share Price Down by 5%; BSE HEALTHCARE Index Down 1.1% (Market Updates)

Aug 11, 2020 | Updated on Aug 11, 2020

STRIDES PHARMA SCIENCE share price is trading down by 5% and its current market price is Rs 611. The BSE HEALTHCARE is down by 1.1%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 4.5%) and ERIS LIFESCIENCES LIMITED (up 2.5%). The top losers are STRIDES PHARMA SCIENCE (down 5.0%) and CAPLIN POINT (down 6.0%).

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS